Treatment de-escalation in HPV-positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives

International Journal of Cancer

Volumn 136, Issue 7, 2015, Pages 1494-1503

  Mirghani, H ^a   Amen, F ^a   Blanchard, P ^a   Moreau, F ^b   Guigay, J ^a   Hartl, D M ^a   Lacau St Guily, J ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Human papillomavirus; Oropharyngeal cancers; PD 1:PD L1 immune checkpoint; PI3K pathway; Treatment de escalation

Indexed keywords

CANCER VACCINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DNA VACCINE; DOCETAXEL; FLUOROURACIL; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN VP16;

CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; ELECTIVE NODAL DOSE DE ESCALATION; FOOD ASPIRATION; HIGH RISK POPULATION; HUMAN; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MEDICAL PROCEDURES; MINIMALLY INVASIVE SURGERY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; ORAL SURGERY; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE REDUCTION; RADIATION INJURY; RISK BENEFIT ANALYSIS; SHORT SURVEY; SMOKING; TRANSORAL ROBOTIC SURGERY; TREATMENT DE ESCALATION; WART VIRUS; CLINICAL TRIAL (TOPIC); COMPLICATION; MULTIMODALITY CANCER THERAPY; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTION; TREATMENT OUTCOME;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME;

EID: 84921000202     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28847     Document Type: Short Survey

References (65)

1. Bouvard V, Baan R, Straif K, et al. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009;10:321-2.
2. Smeets SJ, Braakhuis BJ, Abbas S, et al. Genomewide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006;25:2558-64.
3. Jung AC, Briolat J, Millon R, et al. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int J Cancer 2010;126:1882-94.
4. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
5. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-301.
6. Näsman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125:362-6.
7. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
8. Fakhry C, Westra WH, Li S. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9.
9. Psyrri A, Sasaki C, Vassilakopoulou M, et al. Future directions in research, treatment and prevention of HPV-related squamous cell carcinoma of the head and neck. Head Neck Pathol 2012. doi: 10.1007/s12105-012-0361-8 / Review.
10. Kofler B, Laban S, Busch CJ, et al. New treatment strategies for HPV-positive head and neck cancer. Eur Arch Otorhinolaryngol 2013 Aug 10. [Epub ahead of print].
11. Rischin D. Oropharyngeal cancer, human papilloma virus, and clinical trials. J Clin Oncol 2010;28:1-3.
12. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
13. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 29, No 15-suppl (May 20 Supplement), 2011: 5500.
14. Seiwert T, Fayette J, Cupissol D. A randomized, open-label, phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: final data. Presented at the Multidisciplinary Head and Neck Cancer Symposium, Phoenix, AZ, January 26 , 2012.
15. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. on behalf of the SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013;14:697-710.
16. Farley J, Sill MW, Birrer M, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol 2011;121:303-8.
17. Santin AD, Sill MW, McMeekin DS, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2011;122:495-500.
18. Schilder RJ, Sill MW, Lee YC, et al. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 2009;19:929-33.
19. Mirghani H, Amen F, Moreau F, et al. Oropharyngeal cancers: relationship between epidermal growth factor receptor alterations and human papillomavirus status. in press Eur J Cancer 2014. doi: 10.1016/j.ejca.2013.12.018.
20. Hayes DN, Grandis JR, El-Naggar AK. The Cancer Genome Atlas: integrated analysis of genome alterations in squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2013; 31 (suppl): abstr 6009.
21. Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004;60:1425-39.
22. Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 2007;85:64-73.
23. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2007;68:1289-98.
24. Ensley JF, Jacobs JR, Weaver A, et al. Correlation between response to cis- platinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984;54:811-814.
25. Huang SH, Perez-Ordonez B, Liu FF, et al. Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2012;82:276-83.
26. O'Sullivan B, Huang SH, Perez-Ordonez B, et al. Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol 2012;103:49-56.
27. Pignon JP, le Maître A, Maillard E, et al.; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14.
28. Blanchard P, Bourhis J, Lacas B, et al. Meta-Analysis of Chemotherapy in Head and Neck Cancer Induction Project, Collaborative Group. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the metaanalysis of chemotherapy in head and neck cancer group. J Clin Oncol 2013;31:2854-60.
29. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715.
30. Hitt R, López-Pousa A, Martínez-Trufero J, et al. Phase III study compar- ing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636-8645.
31. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26:3582-3589.
32. O'Sullivan B, Huang SH, Siu LL, et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 2013;31:543-50.
33. Worden FP, Ha H. Controversies in the management of oropharynx cancer. J Natl Compr Canc Netw 2008;6:707-14.
34. Haigentz M, Jr, Silver CE, Corry J, et al. Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol 2009; 266:1845-1855.
35. Weinstein GS, O'Malley BW, Jr, Magnuson JS, et al. Transoral robotic surgery: a multicenter study to assess feasibility, safety, and surgical margins. Laryngoscope 2012;122:1701-7.
36. De Almeida JR, Genden EM. Robotic surgery for oropharynx cancer: promise, challenges, and future directions. Curr Oncol Rep 2012;14:148-57.
37. Dowthwaite SA, Franklin JH, Palma DA, et al. The role of transoral robotic surgery in the management of oropharyngeal cancer: a review of the literature. Isrn Oncology 2012;2012:945162.
38. Ambrosch P, Kron M, Pradier O, et al. Efficacy of selective neck dissection: a review of 503 cases of elective and therapeutic treatment of the neck in squamous cell carcinoma of the upper aerodigestive tract. Otolaryngol Head Neck Surg 2001;124:180-7.
39. Pellitteri PK, Robbins KT, Neuman T. Expanded application of selective neck dissection with regard to nodal status. Head Neck 1997;19:260-5.
40. Sinha P, Lewis JS, Jr, Piccirillo JF, et al. Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer 2012;118:3519-30.
41. Nichols AC, Yoo J, Hammond JA, et al. Earlys-tage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORA-TOR)-study protocol for a randomized phase II trial. BMC Cancer 2013;13:133.
42. Brotherston DC, Poon I, Le T, et al. Patient preferences for oropharyngeal cancer treatment deescalation. Head Neck 2013;35:151-9.
43. Mirghani H, Amen F, Moreau F, et al. Human papilloma virus testing in oropharyngeal squamous cell carcinoma: what the clinician should know. Oral Oncol 2014;50:1-9.
44. Robinson M, Schache A, Sloan P, et al. HPV specific testing: a requirement for oropharyngeal squamous cell carcinoma patients. Head Neck Pathol 2012;6:83-90.
45. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007;121:2465-72.
46. Lewis JS, Jr. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol 2012;6:75-82.
47. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010;28:4142-8.
48. Wasylyk B, Abecassis J, Jung AC. Identification of clinically relevant HPV-related HNSCC: in p16 should we trust? Oral Oncol 2013;49:e33-7.
49. Adelstein DJ, Ridge JA, Gillison ML, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck 2009;31:1393-422.
50. Rietbergen MM, Snijders PJ, Beekzada D, et al. Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas. Int J Cancer 2013. doi: 10.1002/ijc.
51. Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010;116:2166-73.
52. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361:1838-47.
53. Yang W, Song Y, Lu YL, Sun JZ, Wang HW. Increased expression of programmed death (PD)21 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology 2013;139:513-22.
54. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013;73:1733-41.
55. Ukpo OC, Thorstad WL, Lewis JS, Jr. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol 2013;7:113-21.
56. Pai SI. Mission impossible: how HPV-associated head and neck cancers escape a primed immune response. Oral Oncol 2013;49:723-5.
57. Robert C, Soria JC, Eggermont AM. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer 2013;49:2968-71.
58. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
59. Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
60. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154-1157.
61. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333: 1157-1160.
62. Nichols AC, Palma DA, Chow W, et al. High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 2013;139:617-22.
63. Chiosea SI, Grandis JR, Lui VW, et al. PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer 2013;13:602.
64. Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 2013;3:761-9.
65. Molinolo AA, Marsh C, El Dinali M, et al. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. Clin Cancer Res 2012;18:2558-68.